ROCKWELL MEDICAL, INC.: diluted weighted-average shares

What this measure means

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Rockwell Medical's 2024 and 2025 EPS uses loss attributable to common stockholders after Series X preferred-stock accretion, not net loss alone. The accretion is $302,000 in 2024 and $153,000 in 2025, producing common losses of $782,000 and $5,467,000. Potential shares are excluded as anti-dilutive. Dollar losses are displayed in thousands; shares and per-share amounts are unscaled. Full reported share counts and USD EPS are preserved. Read the source filing.

For Rockwell Medical in 2015–2017, stock options, unvested restricted share grants and common-share purchase warrants were excluded from diluted loss per share because their effect would have been anti-dilutive during losses. Basic and diluted weighted-average counts therefore match in the filing. These are full share counts and USD per-share amounts from the historical 2017 report; no later split adjustment is applied to this source version. Read the source filing.

Selected filing history

Related financial histories

• ROCKWELL MEDICAL, INC.: total assets
• ROCKWELL MEDICAL, INC.: total liabilities
• ROCKWELL MEDICAL, INC.: stockholders equity
• ROCKWELL MEDICAL, INC.: cash and cash equivalents
• ROCKWELL MEDICAL, INC.: net income or loss
• ROCKWELL MEDICAL, INC.: operating cash flow
• ROCKWELL MEDICAL, INC.: financing cash flow
• ROCKWELL MEDICAL, INC.: investing cash flow
• ROCKWELL MEDICAL, INC.: retained earnings or deficit
• ROCKWELL MEDICAL, INC.: basic weighted-average shares
• ROCKWELL MEDICAL, INC.: basic earnings per share
• ROCKWELL MEDICAL, INC.: diluted earnings per share
• ROCKWELL MEDICAL, INC.: income tax expense or benefit
• ROCKWELL MEDICAL, INC.: net property, plant and equipment
• ROCKWELL MEDICAL, INC.: share-based compensation expense
• ROCKWELL MEDICAL, INC.: operating income or loss
• ROCKWELL MEDICAL, INC.: current assets
• ROCKWELL MEDICAL, INC.: interest expense
• ROCKWELL MEDICAL, INC.: current liabilities
• ROCKWELL MEDICAL, INC.: current accounts payable
• ROCKWELL MEDICAL, INC.: goodwill carrying amount
• ROCKWELL MEDICAL, INC.: net current accounts receivable
• ROCKWELL MEDICAL, INC.: net inventory
• ROCKWELL MEDICAL, INC.: gross profit
• ROCKWELL MEDICAL, INC.: selling, general and administrative expense
• ROCKWELL MEDICAL, INC.: research and development expense

Inspect the source

Entity

ROCKWELL MEDICAL, INC. / CIK 0001041024

Captured

2026-09-20T05:15:52.429Z

SEC response SHA-256

88e8b83e4e95fda016bcc9a5dced4522c975c40fff65ebdbda5ac42b28ba4fb6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001041024.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))